Patrick Daly

Blood Cancers Today

Isolated CD34-positive cell samples from post-transplant patients with myelodysplastic syndromes (MDS) had significantly higher variant allele frequency (VAF) compared with bulk bone marrow cell samples, according to a study presented at the European Hematology Association 2024 Hybrid Congress.
The study’s method of isolating CD34-positive samples could allow for more sensitive detection of measurable residual disease (MRD) and earlier detection of molecular relapse, according to presenting author Carolin Lindholm, of the Karolinska Institute in Huddinge, Sweden.
Lindholm and colleagues stated that this finding could “potentially improve clinical outcomes since previous studies have indicated that if early signs of relapse could be detected and [treated] pre-emptively, a full hematological relapse may be avoided.”
The researchers used CD34-positive magnetic beads to isolate CD34-positive hematopoietic stem and progenitor cells from vital frozen bone marrow samples collected from post-hematopoietic stem cell transplant patients in the <a href="https://cancercentrum.se/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/nmdsg14-b-2/" target="_blank" rel="noopener">NMDSG14B</a> study. Samples from 28 patients in complete remission and seven patients who relapsed were used to compare the MRD analysis methods.
Overall, MRD was detected via assay in 19 analyses from six patients, and MRD was below the limit of detection in both CD34-positive and bulk bone marrow samples for nine analyses. The authors found that VAF in isolated CD34-positive samples was 3.6 times higher on average (range, 0.3-13.6; P=.0003) compared with matched bone marrow samples.
According to the report, the CD34-positive analysis method could have detected molecular relapse in one out of three patients with available biobank data.
“In summary, we conclude that the method is feasible in a clinical setting, with a higher clonal involvement in the CD34-positive and thereby higher potential to detect molecular relapse earlier than analyzing MRD on [bone marrow],” researchers said.
&nbsp;
Reference
Lindholm C, Mortera-Blanco T, Björklund A, et al. Minimal residual disease in CD34+ cells in myelodysplastic syndrome after allogenic stem cell transplantation. Abstract #P1883. Presented at the European Hematology Association 2024 Hybrid Congress. June 13-16, 2024; Madrid, Spain.

Editor-in-Chief

Associate Editor

Executive Editor

Editorial Board

Isolating CD34-Positive Samples: MRD Analysis in MDS

Meeting News

Isolating CD34-positive samples from patients with MDS was better able to detect molecular relapse.

About Us

Terms of Use

Advertising

Privacy Policy

MashupMD

GU Oncology Now

Cancer Nursing Today

Urban Health Today

DocWire News

eNewsletters

Calendar of Events

Contact Us

Contribute

Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

Leukemia

Aggressive B-Cell Lymphoma

Hodgkin Lymphoma

Indolent B-Cell Lymphoma

Mantle Cell Lymphoma

T-Cell Lymphoma

Lymphoma

Myelofibrosis

Polycythemia Vera

Myeloma

Transplantation & Cellular Therapy

The HemOnc Pulse

The HemOnc Pulse Live

Video Insights

In Print

Subscribe